Autotaxin: A Potential biomarker for primary biliary cholangitis

Area of Science:

• Hepatology
• Biochemistry
• Immunology

Background:

• Diagnosis of primary biliary cholangitis (PBC) can be challenging, often necessitating liver biopsy, particularly in anti-Mitochondrial Antibody (AMA)-negative patients.
• Autotaxin (encoded by the ENPP2 gene) is a secreted lysophospholipase D with potential as a serum biomarker.

Purpose of the Study:

• To investigate autotaxin as a potential serum biomarker for the diagnosis of primary biliary cholangitis (PBC).
• To evaluate the diagnostic accuracy and clinical correlations of autotaxin levels in PBC patients.

Main Methods:

• Plasma samples were analyzed from 103 PBC patients and 74 healthy controls.
• Autotaxin levels were quantified using Enzyme-linked immunosorbent assay (ELISA).
• Statistical analyses determined the predictive value and correlations with clinical data.

Main Results:

• Autotaxin levels were significantly higher in PBC patients (median 60.7 ng/ml) compared to controls (32.6 ng/ml, P < 0.001).
• A cut-off value of 38.5 ng/ml yielded a sensitivity of 54.3% and specificity of 93.1% (AUC=0.73).
• Autotaxin positivity (50.0%) exceeded that of anti-sp100 and anti-gp210 antibodies in AMA-negative PBC patients.

Conclusions:

• Autotaxin demonstrates potential as a non-invasive serum biomarker for diagnosing primary biliary cholangitis (PBC).
• Its utility is particularly noted in AMA-negative PBC cases, potentially reducing the need for liver biopsy.
• Autotaxin levels correlate with IgM and histological staging, suggesting prognostic value.